Zacks Investment Research upgraded shares of Chiasma Inc. (NASDAQ:CHMA) from a hold rating to a buy rating in a research note published on Monday morning. Zacks Investment Research currently has $2.50 price objective on the stock.
According to Zacks, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA. “
Chiasma (NASDAQ:CHMA) opened at 2.05 on Monday. The company’s market capitalization is $49.94 million. Chiasma has a 52 week low of $1.85 and a 52 week high of $24.04. The firm’s 50-day moving average price is $2.45 and its 200 day moving average price is $2.72.
A number of hedge funds have recently made changes to their positions in CHMA. Wellington Management Group LLP increased its stake in shares of Chiasma by 1,074.0% in the first quarter. Wellington Management Group LLP now owns 1,245,265 shares of the company’s stock valued at $11,406,000 after buying an additional 1,139,195 shares during the last quarter. Opaleye Management Inc. acquired a new position in shares of Chiasma during the first quarter worth approximately $183,000. MPM Asset Management LLC increased its position in shares of Chiasma by 1.0% in the second quarter. MPM Asset Management LLC now owns 5,736,296 shares of the company’s stock worth $16,578,000 after buying an additional 54,752 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Chiasma by 25.7% in the second quarter. Vanguard Group Inc. now owns 426,477 shares of the company’s stock worth $1,233,000 after buying an additional 87,259 shares in the last quarter. Finally, A.R.T. Advisors LLC acquired a new position in shares of Chiasma during the second quarter worth approximately $441,000. Hedge funds and other institutional investors own 58.83% of the company’s stock.
Chiasma Company Profile
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.